Back

Menin regulates oncogenic cell identity transcriptional networks in multiple myeloma

Gruber, E.;Kumar, S.;Franich, R.;Khong, T.;Neville, D.;Ang, C.;The, J.;Rumler, B.;Alex, S.;Dobbs, G.;Lewis, A.;Howitt, G.;Hawkins, E.;Bergsagel, P.;Chesi, M.;Spencer, A.;Gilan, O.;Kats, L.

2026-06-19 Cancer Biology
10.64898/2026.06.17.733047 bioRxiv
Show abstract

Multiple myeloma (MM) is a heterogenous cancer that remains mostly incurable. A unifying feature of MM cells is a highly interconnected network of transcription factors and co-factors that coordinate the activity of super-enhancers to enforce myeloma cell identity. Targeting this network offers a promising avenue for therapeutic intervention across genetically diverse myeloma sub-types. Using integrated molecular and functional genomic approaches we identified Menin as a key driver of oncogenic gene expression in MM cells. Menin and its co-factor KMT2A bind at super-enhancers and maintain expression of essential myeloma genes, including IRF4. We demonstrate that Menin inhibitors, which have recently been approved for treatment of acute myeloid leukaemia, are highly active in myeloma cell lines and in vivo models. Combining Menin inhibitors with other super-enhancer targeting therapies such EP300/CREBBP inhibitors or immunomodulatory drugs (IMiDs) overcomes epigenetic plasticity in cells resistant to single agent treatment.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.